PE20011218A1 - Metodo para regular la angiogenesis utilizando proteina ryk - Google Patents

Metodo para regular la angiogenesis utilizando proteina ryk

Info

Publication number
PE20011218A1
PE20011218A1 PE2001000417A PE2001000417A PE20011218A1 PE 20011218 A1 PE20011218 A1 PE 20011218A1 PE 2001000417 A PE2001000417 A PE 2001000417A PE 2001000417 A PE2001000417 A PE 2001000417A PE 20011218 A1 PE20011218 A1 PE 20011218A1
Authority
PE
Peru
Prior art keywords
ryk
refers
disease
cardiovascular
amino acids
Prior art date
Application number
PE2001000417A
Other languages
English (en)
Spanish (es)
Inventor
Nathalie A Dubois-Stringfellow
Alya Zolotorev
Steve Roczniak
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of PE20011218A1 publication Critical patent/PE20011218A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PE2001000417A 2000-05-10 2001-05-10 Metodo para regular la angiogenesis utilizando proteina ryk PE20011218A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56878300A 2000-05-10 2000-05-10

Publications (1)

Publication Number Publication Date
PE20011218A1 true PE20011218A1 (es) 2002-02-01

Family

ID=24272718

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000417A PE20011218A1 (es) 2000-05-10 2001-05-10 Metodo para regular la angiogenesis utilizando proteina ryk

Country Status (13)

Country Link
EP (1) EP1287121A2 (https=)
JP (1) JP2004527206A (https=)
AR (1) AR028424A1 (https=)
AU (1) AU2001261343A1 (https=)
CA (1) CA2408349A1 (https=)
CO (1) CO5300464A1 (https=)
DO (1) DOP2001000164A (https=)
EC (1) ECSP014068A (https=)
GT (1) GT200100079A (https=)
PE (1) PE20011218A1 (https=)
SV (1) SV2002000442A (https=)
UY (1) UY26696A1 (https=)
WO (1) WO2001085789A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1471934A2 (en) * 2002-02-06 2004-11-03 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Kinases involved in the regulation of energy homeostasis
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
EA035674B1 (ru) 2014-07-18 2020-07-24 Санофи Способ определения того, является ли пациент, предположительно страдающий от рака, кандидатом для терапии афлиберцептом
TW202315894A (zh) * 2021-08-18 2023-04-16 美國加利福尼亞大學董事會 抗受體相關酪胺酸激酶（ｒｙｋ）抗體及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0646129A4 (en) * 1992-05-11 1995-07-19 Ludwig Inst Cancer Res MOLECULES, WHICH ARE SIMILAR TO THE TYROSIN KINASE OF THE RECEPTOR TYPE (01/13/94).
AU4606196A (en) * 1994-12-23 1996-07-19 Ludwig Institute For Cancer Research Assay, receptor proteins and ligands
WO1999064589A1 (en) * 1998-06-11 1999-12-16 Astrazeneca Ab Human receptor tyrosine kinase
WO2000024415A2 (en) * 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands

Also Published As

Publication number Publication date
WO2001085789A3 (en) 2002-05-16
WO2001085789A2 (en) 2001-11-15
GT200100079A (es) 2001-12-31
JP2004527206A (ja) 2004-09-09
AU2001261343A1 (en) 2001-11-20
EP1287121A2 (en) 2003-03-05
UY26696A1 (es) 2001-12-28
DOP2001000164A (es) 2002-05-15
ECSP014068A (es) 2002-02-25
SV2002000442A (es) 2002-07-03
CO5300464A1 (es) 2003-07-31
CA2408349A1 (en) 2001-11-15
AR028424A1 (es) 2003-05-07

Similar Documents

Publication Publication Date Title
ES2558330T3 (es) Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo
CR7584A (es) Nuevas proteinas de fusion con trombomodulina dirigidas contra factores tisulares como anticoagulantes
NO993709L (no) Stabilisert blanding omfattende fibrinogen
ES2115662T3 (es) Modificacion genetica de celulas endoteliales.
AR033834A1 (es) Una proteina de fusion para liberar un compuesto a una celula, un metodo para liberar dicho compuesto, un metodo para identificar un peptido penetrador de membranas, y el uso de una proteina de fusion para la manufactura de un agente
ES2146552B1 (es) Peptidos inhibidores de tgf/31
PE20091405A1 (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
PE20090932A1 (es) Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1
CR20110556A (es) Proteinas de fusion rage y metodos de empleo
ATE202115T1 (de) Pth und pthrp analoge deren herstellung und verwendung für die behandlung von osteoporosis.
AR040226A1 (es) Productos parenterales antifungicos
ES2137182T3 (es) Derivados recombinantes del factor viii humano.
ES2167311T3 (es) Bancos de peptidos modificados resistentes a proteasas.
DE69632949D1 (de) Die aktivierung von rezeptoren durch gas6
PT835262E (pt) Metodo para o tratamento de osteopenia induzida por corticosteroides
BR9815142A (pt) "proteìna isolada e modificada; vesicula; método de geração de um complexo proteìco multivalente; de modificação de uma proteìna; de tratamento de um disturbio neurológico; de alteração do estado de crescimento de uma célula; complexo proteìco; polipeptideo de ouriço; polipeptideo de ouriço modificado; proteìna sintética recombinante e uso terapêutico da proteìna"
ES2063370T3 (es) Agentes mejorados para el control biologico de insectos y metodos de uso.
AR117707A1 (es) Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf
DE59207351D1 (de) Verbesserte Aktivierung von rekombinanten Proteinen
ES2055035T3 (es) Un proceso para la preparacion de un glicosido de antraciclina.
PE20011218A1 (es) Metodo para regular la angiogenesis utilizando proteina ryk
ES2545614T3 (es) Proteínas truncadas con nudo de cistina
ES2176202T3 (es) Promotores eucarioticos sinteticos que contienen dos elementos inducibles.
BR0014183A (pt) Composições farmaceuticas e metodos de uso de proteìna relacionada frizzled secretada
ES2066510T3 (es) Nuevos polipeptidos con afinidad para lipopolisacaridos y sus usos.

Legal Events

Date Code Title Description
FC Refusal